FGFR4 and neoplasm: Targeting FGF19 holds therapeutic potential for modulating tumor metabolism by inhibiting the FGFR4-ERK pathway, thereby reducing the expression of key fatty acid synthesis enzymes, such as FASN and ACC, and ultimately disrupting the metabolic support for tumor proliferation.